Drug intelligence / Profile preview

NXC828

Development stage: Preclinical
Lead developer: NEXTGEN Bioscience
Modality: Small Molecules
Administration: Ophthalmic

Overview

NXC828 is a small molecule therapeutic candidate being developed by NEXTGEN Bioscience for the treatment of wet age-related macular degeneration (wet-AMD). It functions by targeting the Hypoxia-Inducible Factor 1-alpha (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) pathways. Through the inhibition of HIF-1α and modulation of VEGF, NXC828 is designed to exert anti-angiogenic effects, addressing the underlying pathology of abnormal vessel growth and leakage in the retina. The program is currently in the preclinical phase of development.

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on NXC828.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXC828.

Explore the full profile